The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
NEJM study shows strong protection across strains
This is an exciting and meaningful milestone for GRIN Therapeutics
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The Danish biotech company confirmed the global study will begin in the second half of 2026
By cutting pain crises & boosting haemoglobin
Subscribe To Our Newsletter & Stay Updated
